Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Audrey Abella, 4 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.

Beauty care improves mental health, quality of life in breast cancer patients

06 Jan 2019
Most of the products involved were not categorised as cosmetics, but were actually pharmaceutical products, which are not registered under the Drug Control Authority.

Beauty care appears to yield short-term and midterm improvements in psychosocial outcomes in patients with early breast cancer, a recent study has found.

The study included 39 female primary breast cancer patients who were randomly assigned to an immediate intervention (n=20; mean age 39.6±9.35 years) or waitlist control (n=19; mean age 37.4±9.60 years) group. The intervention involved a group makeup workshop, a photo session and the receipt of professionally edited photographs.

The intervention had immediate benefits on depressive symptoms. Mean scores dropped from 20.0±5.03 at the start of the session to 15.1±3.33 by the end (p<0.001).

Researchers also observed a short-term benefit of the beauty care intervention. Depressive symptoms were significantly reduced by the first follow-up, which occurred after the immediate intervention but not in the waitlist group had undergone the workshop (MD, –11.9; p=0.001).

This effect persisted until the second follow-up, which took place after the immediate intervention but not in the waitlist group who had received their photos (MD, –8.10; p=0.006). Baseline depressive symptom scores were statistically comparable between the groups (MD, –4.12; p=0.229).

Notably, scores did not differ between the second and third follow-up sessions for both groups, indicating that scores had stabilized by this point.

Similar trends were observed for quality of life, which was significantly higher in the immediate intervention group at both the first (MD, 16.8; p=0.010) and second (MD, 16.7; p=0.009) follow-ups. Baseline values were comparable between groups (MD, 7.85; p=0.271).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date. 
Audrey Abella, 4 days ago
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.